Quantcast
Last updated on April 17, 2014 at 7:54 EDT

Latest Amyotrophic lateral sclerosis Stories

2014-02-19 08:30:37

-- PDE10 Inhibitor Administered to Patients with Huntington's Disease -- SEATTLE, Feb. 19, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being developed for the treatment of schizophrenia, Huntington's disease (HD) and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance...

2014-02-18 23:04:47

Rock stars, celebrity chefs, and rare disease advocates band together to FIGHT MSA, a rare and fatal neurodegenerative disorder. The Multiple System Atrophy Coalition and other MSA groups will be in attendance in a show of solidarity in support of “rock ‘n roll chef” Kerry Simon. Las Vegas, NV (PRWEB) February 18, 2014 A masterful list of superstars comes together for a spectacular fundraiser on February 27, 2014 to support multiple system atrophy (MSA) awareness. MSA is a rare and...

2014-02-16 23:03:37

ALSFight.com Will Provide the Resources and Support Victims of ALS Need to Improve Their Health and Continue Living Meaningful Lives New York, NY (PRWEB) February 16, 2014 ALSFight.com, the ALS start up service dedicated to helping patients who suffer from ALS find ways to manage and treat their disease, is pleased to announce that they have launched a campaign on Indiegogo.com to help them raise funds to create and design their web and mobile application. Amyotrophic Lateral Sclerosis...

2014-02-14 23:01:58

Teams of families and friends of those affected by neuromuscular disease participated in the walk on Feb. 8 at Raymond James Stadium. Saint Petersburg, FL (PRWEB) February 14, 2014 More than $165,000 was raised at the annual MDA Tampa Bay Muscle Walk presented by APEC on Feb. 8 at Raymond James Stadium to benefit children and adults in the Tampa Bay area served by the Muscular Dystrophy Association. Teams of families and friends of those affected by neuromuscular disease participated in...

2014-02-13 12:27:28

More than 500 clubs throughout North America to hold a Group Fitness class on Feb. 22 in support of Augie's Quest, a non-profit searching for a cure for ALS IRVINE, Calif., Feb. 13, 2014 /PRNewswire/ -- In support of Augie's Quest, LA Fitness announced today that it will host an in-club Group Fitness( )class at more than 500 of the company's locations on February 22,( )2014. Augie's Quest is a nonprofit research initiative dedicated to finding treatments and a cure for...

2014-02-11 08:31:37

-- PDE10 Target Engagement Continues to Increase with Well-Tolerated Doses -- SEATTLE, Feb. 11, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. This clinical trial evaluated the extent to which OMS824 binds to PDE10, an enzyme expressed in the region of the brain that has been linked to a wide range of diseases that affect cognition....

2014-02-07 12:51:08

Study in human cells may improve ability to identify useful drug targets In most cases of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, a toxin released by cells that normally nurture neurons in the brain and spinal cord can trigger loss of the nerve cells affected in the disease, Columbia researchers reported today in the online edition of the journal Neuron. The toxin is produced by star-shaped cells called astrocytes and kills nearby motor neurons. In ALS, the death...

2014-02-06 23:01:57

In research funded by the FSH Society, a patient advocacy organization, a Minnesota team has identified drugs that block the toxic effects of a gene involved in a most common form of muscular dystrophy. Lexington, MASS (PRWEB) February 06, 2014 Facioscapulohumeral muscular dystrophy (FSHD) is among the most common muscle-wasting diseases, affecting more than 500,000 people around the world. Its cause is genetic, passed from generation to generation, although 30 percent of cases arise...

2014-02-06 08:29:41

Live Webcast to Air on Tuesday, February 11, at 3:00 p.m. EST ROCKVILLE, Md., Feb. 6, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO Richard Garr will present at the 16(th) Annual BIO CEO & Investor Conference 2014 in New York City on Tuesday, February 11, at 3:00 p.m. EST. Garr will present clinical updates on the company's 2014 NSI-566 cell therapy trials program, including ongoing ALS Phase II; ALS Phase II in Mexico City;...

2014-02-05 23:03:02

A study led by St. Jude Children’s Research Hospital offers a new avenue for scientists to pursue in the quest for desperately needed treatments for ALS Memphis, Tenn. (PRWEB) February 05, 2014 St. Jude Children’s Research Hospital scientists led a study showing that mutations in a gene responsible for amyotrophic lateral sclerosis (ALS) disrupt the RNA transport system in nerve cells. The findings appear in the current issue of the scientific journal Neuron and offer a new focus for...